GSK PLC Sponsored ADR (NYSE:GSK) Receives Average Recommendation of “Reduce” from Brokerages

GSK PLC Sponsored ADR (NYSE:GSK) has been given an average recommendation of “Reduce” by the eight research firms that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation and seven have assigned a hold recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $37.3750.

Several research firms have recently issued reports on GSK. Berenberg Bank reiterated a “hold” rating on shares of GSK in a report on Tuesday, June 3rd. Wall Street Zen raised GSK from a “hold” rating to a “buy” rating in a research note on Sunday, August 3rd. Finally, Hsbc Global Res upgraded GSK to a “strong sell” rating in a research report on Monday, April 28th.

GSK Price Performance

Shares of GSK opened at $39.5970 on Wednesday. GSK has a one year low of $31.72 and a one year high of $44.67. The stock’s fifty day moving average is $38.43 and its 200-day moving average is $38.03. The company has a debt-to-equity ratio of 1.07, a quick ratio of 0.57 and a current ratio of 0.87. The firm has a market capitalization of $80.69 billion, a price-to-earnings ratio of 18.33, a price-to-earnings-growth ratio of 1.70 and a beta of 0.51.

GSK (NYSE:GSK) last posted its quarterly earnings data on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share for the quarter, topping the consensus estimate of $1.12 by $0.11. The business had revenue of $10.64 billion during the quarter, compared to the consensus estimate of $7.92 billion. GSK had a net margin of 10.81% and a return on equity of 49.22%. The company’s quarterly revenue was up 1.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.43 earnings per share. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. Equities analysts anticipate that GSK will post 4.14 EPS for the current year.

GSK Cuts Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 9th. Shareholders of record on Friday, August 15th will be given a $0.4206 dividend. The ex-dividend date is Friday, August 15th. This represents a $1.68 annualized dividend and a yield of 4.2%. GSK’s payout ratio is 77.78%.

Hedge Funds Weigh In On GSK

Several large investors have recently made changes to their positions in GSK. Rexford Capital Inc. bought a new stake in shares of GSK during the 2nd quarter worth $245,000. SkyView Investment Advisors LLC acquired a new stake in shares of GSK during the second quarter worth $303,000. Captrust Financial Advisors lifted its holdings in shares of GSK by 11.0% during the second quarter. Captrust Financial Advisors now owns 85,080 shares of the pharmaceutical company’s stock valued at $3,267,000 after purchasing an additional 8,432 shares during the last quarter. IHT Wealth Management LLC boosted its position in shares of GSK by 12.1% in the 2nd quarter. IHT Wealth Management LLC now owns 14,736 shares of the pharmaceutical company’s stock valued at $566,000 after purchasing an additional 1,589 shares during the period. Finally, BI Asset Management Fondsmaeglerselskab A S increased its stake in GSK by 28.2% in the 2nd quarter. BI Asset Management Fondsmaeglerselskab A S now owns 121,249 shares of the pharmaceutical company’s stock worth $4,656,000 after purchasing an additional 26,685 shares in the last quarter. Institutional investors own 15.74% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.